

3. A pharmaceutical composition comprising a compound of Claim 1, ~~2-oxo-ethylbutanamide~~, or a pharmaceutically acceptable salt or hydrate thereof, in association with a pharmaceutically acceptable carrier.

4. ~~A method of inhibiting Notch signaling in a cancer patient in need thereof, comprising administering a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt or hydrate thereof, to said patient.~~

5. ~~A method of treating a cancer which is T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, erythroleukemia, breast cancer, ovarian cancer, melanoma, lung cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, squamous cell carcinoma (oral), skin cancer or medulloblastoma in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt or hydrate.~~

6. ~~A method of treating a cancer which is T cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, erythroleukemia, breast cancer, ovarian cancer, melanoma, pancreatic cancer, glioblastoma or colorectal cancer in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt or hydrate thereof.~~

7. ~~A compound of Claim 1, or a pharmaceutically acceptable salt or hydrate thereof, for use in therapy.~~

84. A compound of Claim 1, or a pharmaceutically acceptable salt or hydrate thereof, for use in the treatment of a cancer which is T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute meylogenous leukemia, chronic myelogenous leukemia, erythroleukemia, breast cancer, ovarian cancer, melanoma, lung cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, squamous cell carcinoma (oral), skin cancer or medulloblastoma.

95. A compound of Claim 1, or a pharmaceutically acceptable salt or hydrate thereof, for use in the treatment of a cancer which is T-cell acute lymphoblastic leukemia,

chronic myelogenous leukemia, erythroleukemia, breast cancer, ovarian cancer, melanoma, pancreatic cancer, glioblastoma or colorectal cancer.

~~406.~~ Use of a compound of Claim 1, or a pharmaceutically acceptable salt or hydrate thereof, for the manufacture of a medicament for the treatment of a cancer which is T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, erythroleukemia, breast cancer, ovarian cancer, melanoma, lung cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, squamous cell carcinoma (oral), skin cancer or medulloblastoma.

~~417.~~ Use of a compound of Claim 1, or a pharmaceutically acceptable salt or hydrate thereof, for the manufacture of a medicament for the treatment of a cancer which is T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, erythroleukemia, breast cancer, ovarian cancer, melanoma, pancreatic cancer, glioblastoma or colorectal cancer.

~~428.~~ A compound of Claim 1 which is a crystalline hydrate characterized by an X-ray powder diffraction pattern using $\text{CuK}\alpha$ radiation having a peak at 22.97 ± 0.2 degrees 2-theta in combination with one or more peaks at 11.96 ± 0.2 , 18.81 ± 0.2 , 20.78 ± 0.2 or 21.07 ± 0.2 degrees 2-theta at ambient temperature and relative humidity.